{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:35:46Z","timestamp":1740461746617,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"DOI":"10.7759\/cureus.79588","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T02:55:47Z","timestamp":1740452147000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia"],"prefix":"10.7759","author":[{"given":"Kevin T","family":"Dao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"D'Assumpcao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha","family":"Kuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.04.002","article-title":"Bacterial resistance to antibiotics: enzymatic degradation and modification","volume":"57","author":"Wright GD","year":"2005","unstructured":"Wright GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev. 2005, 57:1451-70. 10.1016\/j.addr.2005.04.002","journal-title":"Adv Drug Deliv Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2016.08.007","article-title":"Antibiotic resistance","volume":"10","author":"Frieri M","year":"2017","unstructured":"Frieri M, Kumar K, Boutin A. Antibiotic resistance. J Infect Public Health. 2017, 10:369-78. 10.1016\/j.jiph.2016.08.007","journal-title":"J Infect Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902845630","article-title":"The role of telavancin in the treatment of MRSA infections in hospital","volume":"18","author":"Bassetti M","year":"2009","unstructured":"Bassetti M, Mikulska M, Righi E, Nicolini L, Viscoli C. The role of telavancin in the treatment of MRSA infections in hospital. Expert Opin Investig Drugs. 2009, 18:521-9. 10.1517\/13543780902845630","journal-title":"Expert Opin Investig Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2049936117690501","article-title":"Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens","volume":"4","author":"Das B","year":"2017","unstructured":"Das B, Sarkar C, Das D, Gupta A, Kalra A, Sahni S. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis. 2017, 4:49-73. 10.1177\/2049936117690501","journal-title":"Ther Adv Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173644","article-title":"Treatment for COVID-19: an overview","volume":"889","author":"Stasi C","year":"2020","unstructured":"Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: an overview. Eur J Pharmacol. 2020, 889:173644. 10.1016\/j.ejphar.2020.173644","journal-title":"Eur J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12743","article-title":"Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Lewis PO","year":"2018","unstructured":"Lewis PO, Heil EL, Covert KL, Cluck DB. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther. 2018, 43:614-25. 10.1111\/jcpt.12743","journal-title":"J Clin Pharm Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2021.01.002","article-title":"Daptomycin-induced eosinophilic pneumonia: are there any risk factors?","volume":"51","author":"Ahouansou N","year":"2021","unstructured":"Ahouansou N, Georges M, Beltramo G, Aswad N, Hassani Y, Bonniaud P. Daptomycin-induced eosinophilic pneumonia: are there any risk factors?. Infect Dis Now. 2021, 51:618-21. 10.1016\/j.idnow.2021.01.002","journal-title":"Infect Dis Now"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0623-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides","volume":"57","author":"Al Jalali V","year":"2018","unstructured":"Al Jalali V, Zeitlinger M. Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides. Clin Pharmacokinet. 2018, 57:797-816. 10.1007\/s40262-017-0623-4","journal-title":"Clin Pharmacokinet"},{"key":"ref9","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness WA","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus\u2029. Yale J Biol Med. 2017, 90:269-81.","journal-title":"Yale J Biol Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1139\/cjm-2019-0309","article-title":"Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria","volume":"66","author":"M\u00fchlberg E","year":"2020","unstructured":"M\u00fchlberg E, Umst\u00e4tter F, Kleist C, Domhan C, Mier W, Uhl P. Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria. Can J Microbiol. 2020, 66:11-6. 10.1139\/cjm-2019-0309","journal-title":"Can J Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.056","article-title":"Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients\u00a0with HLA-A\u221732:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype","volume":"147","author":"Nakkam N","year":"2021","unstructured":"Nakkam N, Gibson A, Mouhtouris E, et al.. Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients\u00a0with HLA-A\u221732:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. J Allergy Clin Immunol. 2021, 147:403-5. 10.1016\/j.jaci.2020.04.056","journal-title":"J Allergy Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02824-7","article-title":"Bacterial infections in patients hospitalized with COVID-19","volume":"17","author":"Moreno-Torres V","year":"2022","unstructured":"Moreno-Torres V, de Mendoza C, de la Fuente S, et al.. Bacterial infections in patients hospitalized with COVID-19. Intern Emerg Med. 2022, 17:431-8. 10.1007\/s11739-021-02824-7","journal-title":"Intern Emerg Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.01.005","article-title":"Evolutionary mechanisms shaping the maintenance of antibiotic resistance","volume":"26","author":"Dur\u00e3o P","year":"2018","unstructured":"Dur\u00e3o P, Balbont\u00edn R, Gordo I. Evolutionary mechanisms shaping the maintenance of antibiotic resistance. Trends Microbiol. 2018, 26:677-91. 10.1016\/j.tim.2018.01.005","journal-title":"Trends Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5414\/CP202996","article-title":"A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: a meta-analysis","volume":"55","author":"Liu Y","year":"2017","unstructured":"Liu Y, Wang J. A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Clin Pharmacol Ther. 2017, 55:839-45. 10.5414\/CP202996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225861","article-title":"Impact of chemorophylaxis policy for AIDS-immunocompromised patients on emergence of bacterial resistance","volume":"15","author":"DeNegre AA","year":"2020","unstructured":"DeNegre AA, Myers K, Fefferman NH. Impact of chemorophylaxis policy for AIDS-immunocompromised patients on emergence of bacterial resistance. PLoS One. 2020, 15:e0225861. 10.1371\/journal.pone.0225861","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1075396","article-title":"Antibiotic resistance in patients with primary immunodeficiency disorders versus immunocompetent patients","volume":"11","author":"Mohammadinejad P","year":"2015","unstructured":"Mohammadinejad P, Ataeinia B, Kaynejad K, et al.. Antibiotic resistance in patients with primary immunodeficiency disorders versus immunocompetent patients. Expert Rev Clin Immunol. 2015, 11:1163-72. 10.1586\/1744666X.2015.1075396","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/335315-clinical-telavancin-failure-in-persistent-methicillin-resistant-staphylococcus-aureus-bacteremia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T02:55:51Z","timestamp":1740452151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/335315-clinical-telavancin-failure-in-persistent-methicillin-resistant-staphylococcus-aureus-bacteremia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.79588","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}